Résultats de la recherche

Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights EXTON, PA, March 26, 2025 (GLOBE NEWSWIRE) -- Nearly all nephrologists agree that early and aggressive intervention is essential for improving outcomes in IgA nephropathy (IgAN). However, findings...

Spherix Global Insights and the American Kidney Fund Announce Strategic Partnership and Inaugural Initiative to Elevate the Voice of Kidney Patients – Beginning with IgAN Patients EXTON, PA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights is proud to announce its partnership with the American Kidney Fund (AKF), marking a significant milestone in a collaboration...

Amid Novo Nordisk’s Win for Ozempic’s Expanded Label to Include Chronic Kidney Disease Benefits, Spherix Global Insights Highlights Nephrologists’ Rising Influence in GLP-1 RA Utilization EXTON, PA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- As chronic kidney disease (CKD) management evolves, new findings from Spherix Global Insights’ annual Patient Chart Dynamix™: CKD Non-Dialysis...

Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G often...

US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead Exton, Pennsylvania, Oct. 13, 2023 (GLOBE NEWSWIRE) -- The FDA's recent approvals of Calliditas' Tarpeyo (budesonide) and Travere's Filspari (sparsentan) to treat primary IgA nephropathy (IgAN) have...